Stamakort Peptide: A Research Guide to the A-10 Stomach Bioregulator

Scientifically reviewed by
Dr. Ky H. Le, MD

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

The Stamakort peptide is one of the more closely studied members of the bioregulator class, and much of its appeal in the laboratory comes down to size. Short peptides can be small enough to cross the cell membrane and the nuclear envelope, where they interact directly with DNA (Khavinson et al., 2021).

Within the Khavinson bioregulator system, Stamakort carries the A-10 designation and is associated with gastric tissue. It belongs to a family of organ-derived peptide complexes studied for tissue-directed activity rather than broad, system-wide effects.

This guide reviews what the Stamakort peptide is, how short peptide bioregulators are thought to work, and where the compound fits into in vitro research. All information here is for research use only. Stamakort is not a therapeutic product.

What Is the Stamakort Peptide Bioregulator?

Stamakort is a peptide complex associated with gastric mucosa and labeled A-10 in the bioregulator naming system. It is supplied in capsule format and grouped with the family of low-molecular peptide preparations developed from animal tissue extracts.

The bioregulator concept rests on a simple premise. Each tissue appears to rely on its own set of short regulatory peptides, and a preparation drawn from a given organ is studied for activity on that same organ (Khavinson, 2002).

For a broader primer on this compound class, see our overview of what peptide bioregulators are.

Origins in Khavinson Bioregulator Research

The bioregulator family traces back to research led by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. Their work produced peptide preparations from tissues including the pineal gland, thymus, prostate, and retina (Khavinson, 2002).

From the amino acid profiles of these preparations, the group went on to design short synthetic peptides with tissue-directed activity. Stamakort sits in the gastric branch of this larger program.

How Short Peptide Bioregulators Work

The research interest in short peptides centers on a mechanism that sets them apart from larger proteins. Because of their small size, they can reach the cell nucleus and act at the level of the gene rather than only at the cell surface.

DNA and Gene Expression Regulation

A systematic review of peptide regulation reports that short peptides of two to seven amino acids can penetrate into nuclei, interact with histone proteins, and bind both single- and double-stranded DNA (Khavinson et al., 2021). Through these interactions, peptides are described as modulating DNA methylation and the activation or repression of specific genes.

Molecular docking studies add detail to this picture. Modeling of short peptides against DNA found that several bind defined nucleotide sequences within gene promoter regions, with different peptides recognizing different sites (Khavinson et al., 2016).

Tissue-Specific Activity

The tissue-directed behavior of these peptides has been examined in organotypic culture. In one set of experiments, synthetic peptides stimulated the outgrowth of explants from the tissue matching the peptide’s origin, while leaving unrelated tissues unaffected (Khavinson, 2001).

This selectivity is the main reason the bioregulator family is organized by organ. A gastric-associated peptide such as Stamakort is studied in gastric models rather than as a general-purpose agent. For more on how this class differs from conventional peptides, see bioregulators vs peptides.

The Peptide Theory of Aging and Gastric Tissue

Stamakort is often discussed alongside a broader idea known as the peptide theory of aging. Under this framework, aging is described as a process of changing gene expression that lowers the synthesis of regulatory and tissue-specific peptides, which in turn affects the structure and function of organs (Khavinson, 2002).

The proposed research response is to study whether supplying tissue-matched peptides can support the normal regulatory signals of that tissue in a model system.

Why Organ-Specific Peptides Are Studied Separately

Because each tissue appears to use its own peptide signals, researchers treat organ-derived preparations as distinct compounds rather than interchangeable ones. A retinal peptide, a thymic peptide, and a gastric peptide each carry their own research profile.

This is why a stomach-associated compound is catalogued on its own. Adjacent digestive-organ bioregulators such as Pancragen (pancreas) and Livagen (liver) are studied as separate entries in the same family.

In Vitro Research on Bioregulator Peptides

Much of the laboratory work on this peptide class uses cell culture systems. These models let researchers observe peptide activity on proliferation, differentiation, and gene expression under controlled conditions.

Cell Differentiation and Aging Culture Models

Short peptides have been studied as regulators of cell differentiation, with reports that specific sequences direct pluripotent cells toward particular lineages depending on peptide structure and concentration (Khavinson et al., 2020a).

In aging cell cultures, short peptides at nanomolar concentrations modulated the expression of genes tied to cellular aging, including genes linked to growth signaling and telomere maintenance (Ashapkin et al., 2020). Findings like these shape how researchers design in vitro protocols for the bioregulator family.

Inflammatory and Proliferative Pathways

A 2022 study tested several Khavinson peptides on a monocyte and macrophage cell line. The peptides modulated proliferative signaling, and one of them, the bronchial-derived Chonluten tripeptide, lowered the release of inflammatory markers in cells exposed to bacterial lipopolysaccharide (Avolio et al., 2022).

Work of this kind models how organ-derived peptides behave at the cellular level. For a closer look at one peptide from that study, see our article on Chonluten.

Stamakort Within the Bioregulator Family

Stamakort is one entry in a wider catalog of organ-specific bioregulators, each tied to a different tissue. Grouping them this way reflects the tissue-specific activity reported across the class (Khavinson, 2001).

Researchers comparing compounds within the family often start with the shared mechanism, then narrow to the organ of interest. The table below summarizes potential in vitro research applications studied for short peptide bioregulators.

Research Area	In Vitro / Ex Vivo Application	Supporting Reference
Gene expression	Peptide binding to DNA and effects on gene activation or repression	Khavinson et al., 2021; 2016
Tissue-specific activity	Organotypic explant cultures measuring tissue-matched outgrowth	Khavinson, 2001
Cell differentiation	Models of pluripotent cell lineage direction	Khavinson et al., 2020a
Cellular aging	Nanomolar peptide effects on aging-related gene expression	Ashapkin et al., 2020
Inflammatory signaling	Monocyte and macrophage cell line response to peptide exposure	Avolio et al., 2022

Quality and Sourcing Considerations for Researchers

BioLongevity Labs supplies research compounds with third-party analytical documentation. You can review our approach to third-party testing and our USA-based manufacturing standards.

For laboratory work, compound documentation matters as much as the compound itself. Reproducible results depend on knowing the identity, purity, and consistency of each batch.

Conclusion

The Stamakort peptide is best understood as a research compound rather than a finished product. Its place in the literature comes from the bioregulator model, where short, tissue-directed peptides interact with DNA to modulate gene expression.

For laboratories studying gastric tissue models or the bioregulator class as a whole, Stamakort offers a defined, organ-associated compound with a documented research lineage. All Stamakort research applications are for in vitro and laboratory use only. The compound is not intended for consumption.

References

[1] Khavinson, V. Kh. (2002). Peptides and ageing. Neuro Endocrinology Letters, 23(Suppl 3), 11-144. https://pubmed.ncbi.nlm.nih.gov/12374906/

[2] Khavinson, V. K. (2001). Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine, 132(2), 807-808. doi:10.1023/a:1013058701974

[3] Khavinson, V. K., Popovich, I. G., Linkova, N. S., Mironova, E. S., & Ilina, A. R. (2021). Peptide regulation of gene expression: A systematic review. Molecules, 26(22), 7053. doi:10.3390/molecules26227053

[4] Khavinson, V. K., Lin’kova, N. S., & Tarnovskaya, S. I. (2016). Short peptides regulate gene expression. Bulletin of Experimental Biology and Medicine, 162(2), 288-292. doi:10.1007/s10517-016-3596-7

[5] Khavinson, V., Linkova, N., Diatlova, A., & Trofimova, S. (2020). Peptide regulation of cell differentiation. Stem Cell Reviews and Reports, 16(1), 118-125. doi:10.1007/s12015-019-09938-8

[6] Avolio, F., Martinotti, S., Khavinson, V. K., Esposito, J. E., Giambuzzi, G., Marino, A., … Toniato, E. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. International Journal of Molecular Sciences, 23(7), 3607. doi:10.3390/ijms23073607

[7] Ashapkin, V., Khavinson, V., Shilovsky, G., Linkova, N., & Vanyushin, B. (2020). Gene expression in human mesenchymal stem cell aging cultures: Modulation by short peptides. Molecular Biology Reports, 47(6), 4323-4329. doi:10.1007/s11033-020-05506-3